Page 130 - 《中国药房》2021年13期
P. 130

and congestive heart failure:a nationwide study[J]. Int J  (17):1780-1787.
             Chron Obstruct Pulmon Dis,2017,12:2573-2581.   [27]  康彬,卢飞,安琴燕,等. β-受体阻滞剂治疗慢性阻塞性
        [19]  BHATT S P,WELLS J M,KINNEY G L,et al. β-blockers   肺疾病急性发作并心力衰竭的疗效分析[J].中国继续医
             are associated with a reduction in COPD exacerbations[J].  学教育,2017,9(21):174-177.
             Thorax,2016,71(1):8-14.                        [28]  ADELOYE D,CHUA S,LEE C,et al. Global and regional
        [20]  ZVIZDIC F,BEGIC E,MUJAKOVIC A,et al. Beta-         estimates of COPD prevalence systematic review and
             blocker use in moderate and severe chronic obstructive  meta-analysis[J]. Glob Health,2015,5(2):020415.
             pulmonary disease[J]. Med Arch,2019,73(2):2573-2581.  [29]  VESTBO J,HURD S S,AGUSTÍ A G,et al. Global strate-
        [21]  DU Q,SUN Y,DING N,et al. Beta-blockers reduced the  gy for the diagnosis management and prevention of chro-
             risk of mortality and exacerbation in patients with COPD:  nic obstructive pulmonary disease GOLD executive sum-
             a meta-analysis of observational studies[J]. PLoS One,  mary[J]. Am J Respir Crit Care Med,2013,187(4):
             2014,9(11):e113048.                                 347-365.
        [22]  MACNEE W. Beta-blockers in COPD:a controversy re-  [30]  SU V Y,CHANG Y S,HU Y W,et al. Carvedilol,bisopro-
             solved?[J]. N Engl J Med,2019,381(24):2367-2368.    lol,and metoprolol use in patients with coexistent heart
        [23]  PUENTE-MAESTU L,CALLE M,ORTEGA-GONZÁLEZ            failure and chronic obstructive pulmonary disease[J]. Me-
             A,et al. Multicentric study on the beta-blocker use and re-  dicine(Baltimore),2016,95(5):2427-2434.
             lation with exacerbations in COPD[J]. Respir Med,2014,  [31]  LEITAO FILHO F S,ALOTAIBI N M,YAMASAKI K,
             108(5):737-744.                                     et al. The role of beta-blockers in the management of
        [24]  SUISSA S,ERNST P. Beta-blockers in COPD:a metho-   chronic obstructive pulmonary disease[J]. Expert Rev
             dological review of the observational studies[J]. COPD,  Respir Med,2018,12(2):125-135.
             2018,15(5):520-525.                            [32]  SU T H,CHANG S H,KUO C F,et al. β-blockers after
        [25]  KUBOTA Y,ASAI K,FURUSE E,et al. Impact of β-       acute myocardial infarction in patients with chronic ob-
             blocker selectivity on long-term outcomes in congestive  structive pulmonary disease: a nationwide popula-
             heart failure patients with chronic obstructive pulmonary  tion-based observational study[J]. PLoS One,2019,14
             disease[J]. Int J Chron Obstruct Pulmon Dis,2015,10:  (3):e0213187.
             515-523.                                       [33]  AIZPURUA A B,FRANSSEN F M,EMPEL W,et al. An
        [26]  JABBOUR A,MACDONALD P S,KEOGH M,et al. Dif-        old debate still in the β-phase?[J]. Eur J Heart Fail,2018,
             ferences between betablockers in patients with chronic  20(3):557-559.
             heart failure and chronic obstructive pulmonary disease:a    (收稿日期:2020-11-24  修回日期:2021-05-18)
             randomized crossover trial[J]. J Am Coll Cardiol,2016,55                            (编辑:罗 瑞)












             《中国药房》杂志——《化学文摘》(CA)收录期刊,欢迎投稿、订阅


















        ·1656 ·  China Pharmacy 2021 Vol. 32 No. 13                                 中国药房    2021年第32卷第13期
   125   126   127   128   129   130   131   132   133   134   135